Drug stocks sluggish, but Aastrom soars
March 28, 2011 at 10:19 AM EDT
Drug-sector benchmarks start out the trading week on a flat note, but shares of stem-cell researcher Aastrom soared on a buy rating from Stifel Nicolaus.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|